Abivax SA Schedule 13G passive stakes

TCG Crossover entities have filed an amendment to their Schedule 13G, reporting a combined beneficial ownership of 7.0% in Abivax SA ordinary shares following a recent offering.

Several entities affiliated with Invus Group and Raymond Debbane have collectively acquired a 6.0% stake in Abivax S.A., signaling a notable investment in the biopharmaceutical company.

Invus Public Equities and related entities have reported a 5.0% beneficial ownership stake in Abivax S.A., totaling 3,922,995 ordinary shares.

A group of Venrock entities and individuals have filed an amendment to their Schedule 13G, disclosing a beneficial ownership of 0.8% of Abivax SA's ordinary shares as of September 30, 2025.

TCG Crossover Fund I, L.P., TCG Crossover Fund II, L.P., and their related entities, along with Chen Yu, have disclosed a combined beneficial ownership of 9.1% in Abivax SA as of September 30, 2025.

Deep Track Capital, LP and affiliated entities have updated their beneficial ownership in Abivax SA to 4.78% of outstanding Ordinary Shares.

Invus Public Equities, L.P. and its affiliated entities have disclosed a beneficial ownership of 8.5% in Abivax S.A., holding 5,403,985 ordinary shares.